Genomic Study Maps Shared Risk Factors for 14 Psychiatric Disorders
December 14, 2025
Brand Name :
Urocit-K, Twin K
Synonyms :
Potassium Citrate
Class :
Urinary alkalinizing agents
Dosage Forms & Strengths
Extended-release tablets
5mEq
10mEq
15mEq
Safety study not established
Refer to adult dosing
the serum levels of potassium may be increased
the serum levels of potassium may be increased
the serum levels of potassium may be increased
the serum levels of potassium may be increased
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
may enhance the ulcerogenic activity
may enhance the ulcerogenic activity
may enhance the ulcerogenic activity
may enhance the ulcerogenic activity
may enhance the ulcerogenic activity
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
the activity of dextroamphetamine transdermal may be increased
the serum levels of potassium may be increased
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
anticholinergic agents increase the ulcer-producing effect of potassium citrate
may increase the ulcerogenic effect of anticholinergic agents
may increase the ulcerogenic effect of anticholinergic agents
may increase the ulcerogenic effect of anti-cholinergic agents
may increase the ulcerogenic effect of Anticholinergic Agents
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
potassium citrate: they may increase the CNS depressant effect of CNS Depressants
the serum levels of potassium may be increased
the serum levels of potassium may be increased
the serum levels of potassium may be increased
by inhibiting gastrointestinal absorption, the levels of potassium citrate may be decreased
the serum levels of potassium may be increased
the serum levels of potassium may be increased
the activity of disopyramide may be increased due to pharmacodynamic synergism
the serum levels of potassium may be increased
by reducing elimination, the level of potassium citrate may be increased
the serum levels of potassium may be increased
the serum levels of potassium may be increased
Actions and spectrum:
The citrate in potassium citrate binds to urinary calcium and alkalinizes urine
Frequency not defined
Pain in the abdomen
Chest pain
Loss of movement
Irregular heartbeat
Severe vomiting
bloody stools
coughing up blood is a sign of bleeding in the stomach
diarrhea
upset of stomach
Black Box Warning
To be used with caution in patients suffering from cardiovascular diseases
Contraindication/Caution:
Contraindication:
Hypersensitivity
Heart problems
Kidney stones
Stomach ulcer
Crohn’s disease
Ulcerative colitis
Pregnancy consideration:
USFDA pregnancy category: C
Lactation:
Data about the excretion of potassium citrate into breast milk is not known.
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Pharmacodynamics:
Potassium citrate alters the urine in a way that makes it less likely for salts like uric acid, calcium phosphate, and oxalate to crystallize and form stones.
Pharmacokinetics:
Absorption
Onset: 1hour
Distribution
Metabolism
Potassium citrate undergoes hepatic metabolism, the active metabolite being bicarbonate
Elimination and excretion
Mostly eliminated through urine
Half-life:
Administration:
Take the tablet with or within food half an hour after bedtime snacks or meals.
Patient information leaflet
Generic Name: potassium citrate
Why do we use potassium citrate?
Potassium citrate is used or the treatment of uric acid lithiasis, with or without the presence of calcium stones, hypocitraturic calcium oxalate nephrolithiasis, and renal tubular acidosis.